Journal: Journal of Fungi

Article Title: An Overview on Candida auris in Healthcare Settings

doi: 10.3390/jof9090913

Figure Lengend Snippet: Summary of CDC algorithm ([ 32 ], modified).

Article Snippet: GenMark ePlex BCID-FP Panel , , Yes , n/a.

Techniques: Modification, Software

Journal: Frontiers in Medicine

Article Title: Rapid Antimicrobial Susceptibility Testing Methods for Blood Cultures and Their Clinical Impact

doi: 10.3389/fmed.2021.635831

Figure Lengend Snippet: Select genotypic tests that are approved for rapid detection of resistance markers in positive blood cultures.

Article Snippet: ePlex ® BCID-GN (GenMark) , 21 Gram-negative targets “pan” Gram-positive target “pan” Candida target , Carbapenemases bla IMP bla KPC bla OXA −48/ OXA −23 bla NDM bla VIM ESBL bla CTX − M , ( ) .

Techniques: Bla VIM Assay, Luminex

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: Although the GenMark ePlex BCID demonstrated statistically higher mean DOOR-MAT scores than Verigene BC, both the immediate impact on an individual patient’s clinical outcome and the long-term impact on antimicrobial resistance is unknown.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: Although the GenMark ePlex BCID demonstrated statistically higher mean DOOR-MAT scores than Verigene BC, both the immediate impact on an individual patient’s clinical outcome and the long-term impact on antimicrobial resistance is unknown.

Techniques:

Journal: FEMS Microbiology Reviews

Article Title: Recent trends in molecular diagnostics of yeast infections: from PCR to NGS

doi: 10.1093/femsre/fuz015

Figure Lengend Snippet: Survey of available methodologies for fungal diagnostics, including commercially available kits, with indication of assay and manufacturer, biomarker, principle, scope, sensitivity and specificity, approval information, limit of detection (LoD), time, clinical sample and reference work.

Article Snippet: ePlex BCID-FP (GenMark DX) , DNA—r.f.u. , 19 Candida spp. , I , u.d./u.d. , u.d. , — , 1.5 h , Blood culture , Maubon et al . .

Techniques: Biomarker Discovery, Real-time Polymerase Chain Reaction, Multiplex Assay, Mutagenesis, Clinical Proteomics, Control, Enzyme-linked Immunosorbent Assay, Lateral Flow Assay, Agglutination, Bacteria, Isolation

Journal: Microbiology Spectrum

Article Title: Correlation between Identification of β-Lactamase Resistance Genes and Antimicrobial Susceptibility Profiles in Gram-Negative Bacteria: a Laboratory Data Analysis

doi: 10.1128/spectrum.01485-21

Figure Lengend Snippet: Distribution of Gram-negative bacteria identified by MALDI-ToF and ePlex from March 2019 to February 2021

Article Snippet: The use of rapid molecular diagnostic (RMD) tests such as GenMark ePlex BCID-GN panel allows surveillance of CTX-M ESBL and common carbapenemases at a molecular level in Gram-negative bacteria.

Techniques: Bacteria